To compare outcomes with early corticosteroid withdrawal (CSWD) and chronic low dose corticosteroid therapy (CCS). Summary Background Data: Final, 5-year results from the first randomized, double-blind, placebo-controlled trial of early CSWD (at 7 days posttransplant) are presented. Methods: Adult recipients of deceased and living donor kidney transplants without delayed graft function were randomized to receive prednisone (5 mg/d after 6 months posttransplant) or CSWD. Blinding was maintained for 5 years. This clinical trial is registered at www.clinicaltrials.gov (NCT00650468). Results: Results in 386 patients CSWD (n ϭ 191), CCS (n ϭ 195) are presented (CSWD; CCS). No differences were observed at 5 years in the proportion of patients experiencing: primary end point (composite of death, graft loss, or moderate/severe acute rejection) (30/191 (15.7%); 28/195 (14.4%)), patient death (11/191(5.8%);13/ 195 (6.7%)), death-censored graft loss (11/191 (5.8%); 7/195(3.6%)), biopsy confirmed acute rejection (BCAR) (34/191 (17.8%); 21/195 (10.8%), P ϭ 0.058), moderate/severe acute rejection (15/191 (7.9%); 12/195 (6.2%)). Kaplan Meier analyses of the primary end point and its components also showed no differences; but BCAR was higher with CSWD (P ϭ 0.04). Increased BCAR episodes were primarily corticosteroid-sensitive Banff 1A rejections: the incidence of antibody-treated BCAR was similar between groups (11/191 (5.8%); 13/195 (6.7%)). No differences in renal function were observed at 5 years: mean serum creatinine (1.5 Ϯ 0.6; 1.5 Ϯ 0.7 mg/dL), or Cockroft Gault calculated creatinine clearance (58.6 Ϯ 19.7; 59.8 Ϯ 20.5 mL/min). CSWD was associated with improved serum triglycerides (evaluated by mean and median change from baseline) at all time points (except at 5 years measured by mean change). Weight change also demonstrated changes favoring CSWD (median change from baseline at 5 years: 5.1 vs. 7.7 kg, P ϭ 0.05). New onset diabetes after transplant (NODAT) was similar with respect to proportions who required treatment (23/107 (21.5%)); 18/86 (20.9%); however, fewer CSWD patients required insulin for NODAT at 5 years (4/107 (3.7%)); 10/86 (11.6%), P ϭ 0.049). Changes in HgA1c values (from baseline) were lower in CSWD patients at all time points except 4 years. Conclusions: Early CSWD, compared with CCS, is associated with an increase in BCAR primarily because of mild, Banff 1A, steroidsensitive rejection, yet provides similar long-term renal allograft survival and function. CSWD provides improvements in cardiovascular risk factors (triglycerides, NODAT requiring insulin, weight gain). Tacrolimus/MMF/antibody induction therapy allows early CSWD with results comparable to long-term low dose (5 mg/d) prednisone therapy.
T he morbidities induced by corticosteroids are protean in their manifestations and substantial in their severity. Moreover, corticosteroids have historically been responsible for a significant proportion of the morbidity experienced by kidney transplant recipients. The magnitude of their adverse effects were recognized with their initial use in kidney transplantation, 1 and in the following 5 decades, transplant professionals persistently tried to reduce or eliminate their use. However, successes in reducing corticosteroid exposure have been limited primarily by the risk of acute rejection and the perceived threat of late renal allograft loss. It is not surprising, therefore, that significant advances in reducing corticosteroid dosing have occurred in surges concurrent with introduction of newer and more potent immunosuppressive regimens.
In the mid-1990s, initial experiences with corticosteroid withdrawal (CSWD) after tacrolimus rescue therapy were reported in kidney transplant recipients. 2, 3 These 2 single center experiences provided similar results and indi-cated that tacrolimus-based immunosuppression allowed CSWD even in patients with refractory renal allograft rejection. The observation that complete CSWD could be achieved in the "worst of the worst rejectors" provided a cogent reason to explore the potential for eliminating maintenance corticosteroid therapy in the early posttransplant period.
FDA approval of mycophenolate mofetil (MMF) in 1995 provided another means for enhancing maintenance immunosuppression. Three months later, in December 1995, the first patients were treated with early CSWD under the tacrolimus/MMF combination, and this experience was reported in 1998. 4 This initial experience provided the foundation for this double-blinded multicenter study, and was unique in several respects. First, the preliminary evidence showed that low acute rejection rates (21% at 1 year) could be achieved with early CSWD under tacrolimus/MMF immunosuppression. Second, the experience provided initial evidence that early CSWD could be achieved with low acute rejection rates in 3 populations long thought to be ineligible for CSWD because of their high acute rejection risk-highly sensitized, repeat transplant, and African American recipients. Finally, this experience also described a novel approach for reducing acute rejection risk by identifying and addressing the problem of leukopenia-induced dose limitation of antiproliferative agents by acceptance of lower peripheral WBC counts. Ten years after this report, the tacrolimus/MMF regimen is now the most commonly used maintenance immunosuppressive for early CSWD in the United States. 5 A primary consideration in the design of this prospective, multicenter trial was to address the major barrier that has prevented effective reductions in corticosteroid therapy. This barrier, viz, concern over the threat of increased late renal allograft loss, originated from observations in the doubleblinded Canadian multicenter CSWD trial. 6 This study demonstrated a small (8%) but significant increased risk of late (ie, beyond 3 years post-transplant) renal allograft loss with CSWD. The influence of this observation is difficult to overestimate, as it has been the primary reason why transplant surgeons and physicians have been reluctant to withdraw corticosteroids in renal transplant recipients. Moreover, for over 2 decades, no data from double-blinded trials have been produced to refute this observation. One of the most important design considerations for this double-blinded trial, therefore, was to determine whether a more potent immunosuppressive regimen (tacrolimus/MMF with induction antibody therapy) would eliminate the negative effects of early CSWD on long-term renal allograft survival and function that were observed in the Canadian multicenter CSWD trial. 6 This report presents the final 5-year results from this study.
METHODS
This clinical trial is registered at www.clinicaltrials.gov (NCT00650468). CONSORT Criteria. This report meets all CONSORT criteria ( Table 1) for publication of randomized trials. 7 (Human subjects protection.) The study protocol was IRB approved at each study site and conducted according to IRB standards at each institution. Informed consent was obtained before en-rollment. Participants: Inclusion criteria included: (1) primary deceased and live donor transplant patients aged 18 to 70 years, (2) 30% reduction in serum creatinine from pretransplant within 3 to 7 days without dialysis, (3) repeat transplant recipients whose prior renal allograft loss was due to technical reasons and whose panel reactive antibody (PRA) did not exceed 25% after allograft loss, or loss because of recurrent diseases except FSGS, (4) female patients of child bearing potential with negative pregnancy test and agreed to practice birth control while receiving MMF. Exclusion criteria included: (1) peak PRA Ն50%, (2) current PRA Ն25%, (3) multiple organ transplants, (4) cold ischemia time over 36 hours, (5) nonheart beating donor kidney recipients, (6) pediatric donor kidney recipients, (7) donor age Ͼ65 years), (8) HLA identical live donor transplants, (9) patients requiring corticosteroids that could not be discontinued, (10) HIV seropositivity, (11) pregnancy, (12) dual kidney transplants, and (13) acute rejection before posttransplant day (PTD) 7. Study objective and hypothesis: The study objective was to compare early CSWD with chronic corticosteroid therapy (CCS) under tacrolimus/MMF-based immunosuppression with antibody induction. The study hypothesis was early (7 day) CSWD, under tacrolimus/MMF/antibody induction, would provide equivalent results to chronic low-dose prednisone therapy (5 mg/d after 6 months) in the primary composite end point of death, graft loss, and moderate/severe acute rejection at 5 years. Outcomes: All endpoints were evaluated at 6 months, and yearly thereafter to 5 years. The primary end point was a composite of death, graft loss, or moderate/severe acute rejection (Banff grades 95 Ն 2B or 97 Ն 2A) 6 or acute rejection requiring antilymphocyte antibody). The primary end point was to be evaluated by timeto-event Kaplan Meier analysis and by 2 analysis of final 5-year data. Secondary endpoints included: (1) patient and graft survival, (2) study drug discontinuation, (3) Framingham coronary heart disease risk estimates, 8 (4) frequency, severity, and treatment of acute rejection, (5) frequency, severity, and treatment of new onset of diabetes mellitus after transplantation (NODAT), (6) frequency severity and treatment of hypertension, (7) hyperlipidemia (serum cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides), (8) hyperlipidemia therapy, (9) weight, (10) infection, (11) malignancy, (12) calculated creatinine clearance (Cockroft Gault), 9 (13) serious adverse events (SAEs), and (14) leukopenia. Sample size determination: Assuming a rate of 10% in the primary end point in the CCS group, 312 patients were required to detect a 10% increase in the CSWD group for an alpha error of 5% (one-tailed) and statistical power of 80%. Randomization: sequence generation: Patients were randomized 1:1 with stratification by race (African American or not) and donor type (living or deceased) to CSWD at 7 days (CSWD group) or chronic corticosteroid therapy (CCS group). Randomization was based on a permuted block design with block sizes of 6 within each clinical site. Randomization and allocation concealment: The EMMES Corporation generated the allocation sequence and maintained the allocation code. Randomization was performed by central randomization service (EMMES) and concealed until intervention assignment. The randomization order did not have a repeating sequence, and the randomization code was not broken or revealed to patients/investigators until subjects completed study. Implementation: Patients were enrolled by study site personnel. Blinding: Study subjects, investigators, study personnel, and those assessing outcomes remained blinded throughout 5-year duration of the study, unless medical necessity to unblind occurred. Blinding period was planned for 5 years. DSMB, Interim Analyses, and Stopping Criteria: This study was monitored by a DSMB that met regularly to review unblinded data. The DSMB was charged specifically to review the primary end point, the individual components of the primary end point, and acute rejection rates. Absolute stopping criteria were not predefined; rather a group sequential monitoring plan based on O'Brien-Fleming was used as a guide to set boundaries for interim monitoring of the primary end point. In addition, the DSMB also had available all secondary end point data, and data management and analytic expertise from EMMES to perform additional data analyses if needed. Interim unblinded data analysis was performed yearly, beginning at 2 years. Interim analyses were added because large numbers of patients in the United States were receiving early CSWD, and the results of this trial were considered important to assure that early CSWD was indeed safe. Interventions and Treatment Protocol-Immunosuppression. Immunosuppression dosing was based on actual body weight. Tacrolimus was initiated within 72 hours posttransplant at 0.15 to 0.2 mg/kg/d. Target trough levels of 10 to 20 ng/mL were to be reached by PTD 7 and maintained to PTD 90; beyond PTD 90 target levels were 5 to 15 ng/mL. MMF 1 g was given preoperatively and postoperatively it was given as 2.0 g/d intravenous (IV), or 3.0 g/d orally (all patients given oral from PTD 3-14), after which dose was reduced to 2.0 g/d. MMF dosing guidelines minimized leukopenia-induced MMF dose limitation: WBC Ͼ3000 cells/uL-no change, WBC Ͼ2000 -decrease dose by 500 to 1000 mg/d, WBC Ͻ2000 with ANC Ͼ1000 -decrease dose by 50%, ANC Ͻ1000 cells/uL, discontinue until ANC Ͼ1000 cells/uL. Induction therapy was determined per center preference with IL-2R antibody (basiliximab or dacluzimab per package insert) or thymoglobulin (1.5 mg/kg ϫ 4 doses). All patients received unblinded corticosteroids for the first 7 days after transplantation. On PTD 8, patients received blinded study drug as capsules (CSWD group-placebo; CCS group-prednisone). Prednisone dosing in the CCS group was: PTD 8 to 14 0.4 mg/kg; PTD 15 to 29 0.3 mg/kg; PTD 30 to 89 (0.2 mg/kg); PTD 90 to 119 (0.15 mg/kg), PTD 120 to 180 (0.1 mg/kg); PTD Ͼ180 (5 mg/d).
Diagnosis and Treatment of Acute Rejection. Baseline serum creatinine was defined as the median of 5 consecutive serum creatinine determinations before rejection. Acute rejection was defined as an elevation of serum creatinine of 20% above baseline or an absolute increase of Ͼ0.4 mg/dL with biopsy showing Banff grade 1A or greater. 10 Acute rejection episodes were treated according to Banff criteria 10 : Banff '95 Grade Ͻ 2B or Banff '97 Ͻ 2A (mild acute rejection): Days 1 to 3 IV methylprednisolone 7 mg/kg/d (maximum 500 mg/d), followed by a defined oral prednisone taper. At 180 days postrejection, prednisone 5 mg/d was given or blinded study drug restarted if serum creatinine was less than 30% above prerejection baseline. Acute rejection episodes with Banff grades Banff 95 Grade Ն 2B or Banff '97 Ն 2A (moderate/severe acute rejection) were treated with OKT3, ATGAM, or thymoglobulin for 10 to 14 days with long-term maintenance corticosteroids per institutional practice. For purposes of data analysis, moderate/severe acute rejection was defined as a Banff 95 Grade Ն 2B or Banff '97 Ն 2A rejection or any rejection episode that required antilymphocyte antibody therapy. Infection and ulcer prophylaxis: Antibiotic, antifungal, peptic ulcer, CMV, and PCP prophylaxis were required and conducted by each center as per standard practice with therapy consistent for all study patients. Data Collection and Statistical Methods. Data were entered manually on case report forms by transplant coordinators at individual study sites. Case report forms were finalized by end of study visits to each study site by Astellas personnel. Individual sites were monitored on site at regular intervals by Astellas personnel for protocol compliance and source document verification of case report form data. The master SAS database was created at EMMES from case report form data, and the database was finalized and locked in February 2008. Data were analyzed on an intent-to-treat basis. Means for continuous variables were compared using a t test and medians using a Wilcoxon rank sum test. Categorical frequencies were compared using Pearson's 2 test or Fisher exact test, as appropriate. Differences in time to event data were analyzed using Kaplan-Meier product limit estimates and log-rank test. Multivariate analyses are based on logistic regression or Cox proportional hazards modeling. Statistical analyses were performed using SAS, and 2-tailed tests of significance were used in all instances. No differences were noted between study groups with respect to demographic, immunologic risk, induction therapy, and stratification ( Table 2 ). Stratification provided equivalent patient subgroup allocation (Table 2) . Treatment Analyses-Immunosuppression. Proportions of patients receiving rabbit antithymocyte globulin (thymoglobulin) and IL-2R antibody induction in the CSWD and CCS groups were similar ( Table 2 ). Immunosuppressive drug exposure: Tacrolimus trough levels were similar between groups ( Fig. 2A ). MMF dosing, however, was significantly lower in the CSWD group between 4 weeks and 3 years ( Fig.  2B ). Beginning at week 4, CSWD patients experienced greater reductions from baseline in WBC counts at all time points during the study (Fig. 2C ). . 1 ) were similar between groups (CSWD 67/191 (35.1%); CCS 73/195 (37.4%)). Most common reasons for drug discontinuation were (number of patients, CSWD, CCS): acute rejection/suspected rejection (11, 12) , patient decision/consent withdrawal (13, 14) , noncompliance (7, 10) , and polyomavirus nephropathy (2, 6) . Outcomes and Estimation for Primary and Secondary Endpoints. No differences were observed between groups at 5 years with respect to the proportions of patients reaching the primary composite end point (CSWD 30/191 (15.7%); CCS 28/195 (14.4%)), or its individual components of patient Renal function at 5 years assessed by mean serum creatinine (CSWD 1.5 Ϯ 0.6; CCS 1.5 Ϯ 0.7 mg/dL) and Cockroft Gault calculated creatinine clearance at 5 years (CSWD 58.6 Ϯ 19.7; CCS 59.8 Ϯ 20.5 mL/min) were almost identical between groups (Figs. 2D, E). No differences were observed in the proportions of patients in CSWD and CCS groups with calculated creatinine clearance at 5 years of Ͻ20 mL/min, Ͻ40 mL/min, Ͻ60 mL/min, and Ͻ80 mL/min ( Fig. 2F) . Cardiovascular Risk Endpoints. Cardiovascular risk factor data are presented in Figure 4A -H. No differences were observed with respect to systolic or diastolic blood pressure, HDL and LDL cholesterol, or NODAT defined as 2 occurrences of fasting glucose Ն126 mg/dL. Statistically significant improvements in serum triglycerides (evaluated by mean and median change from baseline) were observed in all CSWD patients or those without pre-existing hyperlipidemia at all time points with one exception (5 years in the mean change only for all patients (Fig. 4D ). Total serum cholesterol change over time data indicated greater reduction with CSWD through month 12, but no statistical significance was noted between study groups at 5 years (Fig. 4E) . No difference occurred in the proportion of patients receiving antilipid therapy at baseline (CSWD (30.4%); CCS (28.7%), P ϭ NS) or at 5 years (CSWD (62.1%); CCS (73.5%), P ϭ 0.053); however the proportions of patients who required institution of antilipid therapy and remained on antilipid therapy at the end of the study was higher in CCS group: (CSWD (50.6%); CCS (67.0%), P ϭ 0.038). At 5 years, the proportions of patients with NODAT requiring therapy were similar between groups (23/107 (21.5%); 18/86 (20.9%)); however, the proportion of patients with NODAT requiring insulin at 5-years posttransplant was lower with CSWD (CSWD 4/107 (3.7%); CCS 10/86 (11.6%), P ϭ 0.049). The change in HgA1c from baseline was statistically significantly smaller at all time points (except 48 months) in NODAT patients in CSWD group, indicating that diabetic control for NODAT is better with CSWD despite less insulin use. Weight change demonstrated changes favoring CSWD expressed as median change from baseline at 5 years: 5.1 versus 7.7 kg, P ϭ 0.05, yet no differences were observed in mean weight change between groups. Figure 4G presents (Table 3 ). No differences occurred through 5 years in cataract incidence (Table 3) . Table 4 presents a summarization of corticosteroid-related morbidity. SAE, adverse events, hospitalization, infection, and malignancy data through 5 years are presented in Table 3 . SAE data revealed a trend toward a higher proportion of patients with SAEs in the CCS group. The CCS group experienced more infectious and diabetes-related SAE. The CSWD group experienced more hyperkalemia-related SAE, possibly because of loss of mineralocorticoid activity after CSWD. Infection: No differences were noted between groups for all infections, CMV disease, fungal infections, or biopsyconfirmed polyomavirus nephropathy (Table 3 ) Malignancies: No differences were noted between groups for all malignancies, skin cancer, or posttransplant lymphoproliferative disorder (Table 3) . Subgroup Analyses. Biopsy-proven acute rejection rates were numerically lower with thymoglobulin induction than IL-2 receptor antibody in CSWD patients, but were not statistically significant (18/125 (14.4%); 16/66 (24.2%), P ϭ 0.09) ( Fig. 3F ). African Americans did not experience increased rates of biopsy-proven acute rejection with CSWD (CSWD 6/34 (17.6%); CCS 8/42 (16.7%)). Biopsy-proven acute rejection rates were similar between groups in patients receiving deceased donor kidney transplants (CSWD 15/83 (18.1%); CCS 8/83 (9.6%) P ϭ 0.177) or living donor kidney transplants (CSWD 19/108 (17.6%); CCS 13/112 (11.62%) P ϭ NS). Adjusted Analyses. Cox proportional hazards model analysis of risk factors for biopsy-proven acute rejection did not reveal any factors to be statistically significant including: CCS versus CSWD (RR 0.599 (CI 0.344 -1.045), P ϭ 0.071), recipient age Ͼ60 versus Ͻ60 (RR 0.415 (CI 0.129 -1.341), P ϭ 0.14), thymoglobulin versus IL2R antibody induction (RR 0.683 (CI 0.391-1.190), P ϭ 0.178), diabetic versus nondiabetic recipient (RR 0.605 (CI 0.300 -1.220), P ϭ 0.160), living donor versus deceased donor (RR 0.978 (CI 0.551-1.736), P ϭ 0.938), male versus female recipient (RR Additional Post Hoc Analyses. The study protocol did not include protocol biopsies, therefore all biopsies performed in study subjects were for cause biopsies. Chronic allograft nephropathy (CAN) incidence and biopsy rates were not predefined endpoints in the study. A 5.8% increase in CAN was noted in the CSWD group through 5 years (9.9% vs. 4.1%, P ϭ 0.028). A greater proportion of CSWD patients underwent for cause renal allograft biopsies (CSWD 88/191 (46.1%)); CCS (64/195 (32.8%), P ϭ 0.009). However, of the patients who underwent renal allograft biopsy, CCS patients had a higher mean number of biopsies per patient (CSWD 141 biopsies in 88 patients (1.602 biopsies/patient)); CCS 125 biopsies in 64 patients (1.95 biopsies/patient). Median biopsies/patient was not statistically significant (CSWD 1.0; CCS 1.5, P ϭ 0.13). Over half of the patients diagnosed with CAN, had CAN diagnosed on their first renal allograft biopsy (CSWD 13/19 (68.4%);CCS 6/8 (75%)). Therefore, these patients could not have preexisting donor kidney disease excluded as the etiology of CAN.
RESULTS

Recruitment. Enrollment started in
Outcomes in patients with CAN did not appear different between groups: death (CSWD 1/19 (5.3%); CCS 1/8 (12.5%), P ϭ S) and renal allograft loss (CSWD 8/19 (42.1%); CCS 2/8 (25%), P ϭ NS). Outcomes in patients without CAN also did not seem different between groups: death (CSWD 10/172 (5.8%); CCS 12/187 (6.4%), P ϭ NS) and renal allograft loss (CSWD 3/172 (1.7%); CCS 5/187 (2.7%), P ϭ NS). Renal function determinations (assessed by Cockroft Gault calculated creatinine clearance) after CAN diagnosis demonstrated similar renal function between study groups: (CSWD 32.1 Ϯ 17.5; CCS 34.6 Ϯ 18.5 mL/min, P ϭ NS).
DISCUSSION
Only 2 prospective, randomized, double-blind trials of CSWD have been completed in renal transplantation (Table  5 ). 6, 15 A third trial was initiated but did not define early immunosuppression and was halted early when acute rejection rates exceeded stopping criteria. 12 The present study differs from these previous double blinded CSWD studies in that it: (1) used tacrolimus rather than cyclosporine, (2) discontinued corticosteroids in the early posttransplant period (7 days compared with 90 days and beyond), (3) used induction therapy in all patients, and (4) had a longer blinding period of 5 years (Table 5) .
Several trial design considerations derived from observations in the preliminary early CSWD experience 4 including: (1) tacrolimus/MMF maintenance immunosuppression, (2) corticosteroid cessation after the seventh PTD, (3) aggressive tacrolimus and MMF loading during the first 7 PTDs to provide Preparations for design of this multicenter prospective trial included a review of pertinent clinical corticosteroid withdrawal trials available in the late 1990s. 6, 13, 16, 17 Review of these studies indicated that in all CSWD trials up to that time, the primary end point was the incidence of acute rejection. In addition, the end points in most trials focused on quantitating risks rather than benefits of CSWD. This trend may have occurred because many benefits were difficult to quantitate, and techniques for quantitating some of the benefits were not widely available. Examples include cosmesis (acne and Cushingoid disfiguration), wound healing, bone complications, dermal atrophy, cataracts, noncompliance, and steroid myopathy. Therefore, end points that evaluated the benefits of CSWD and could be measured objectively were included in the present study, particularly cardiovascular risk factors (hypertension, cholesterol, triglycerides, NODAT). In addition, end points that do not have well accepted definitions, such as NODAT, were evaluated by multiple definitions and multiple parameters. Trial design considerations for the study population (ie, inclusion/exclusion criteria) were also influenced by the Canadian multicenter CSWD trial 6 and other historical CSWD trials 6, 13, 16, 17 and also by our initial early CSWD experience. 4 Experiences in these trials indicated that highly sensitized patients, repeat transplant recipients, and deceased donor transplant recipients were at increased acute rejection risk with CSWD. Highly sensitized primary and repeat transplant recipients (except those with prior kidney transplant loss for technical reasons or recurrent disease) were, therefore, excluded from the present trial. Deceased donor transplant recipients were included; however, those with delayed graft function, a known risk factor for acute rejection, were excluded. Finally, patients in the Canadian multicenter CSWD trial were significantly under-immunosuppressed as they were maintained only on the cyclosporine (Sandimmune) monotherapy, with low trough levels (Ͻ115 ng/mL mean population level) for the first 3 years. This consideration was addressed in the present trial design by employing (1) the more potent tacrolimus/MMF maintenance immunosuppression and (2) induction antibody therapy, specifically to reduce the risk of acute rejection and late renal allograft loss with early CSWD.
Considerations of Study Hypothesis and Study Results.
The underlying hypothesis for the study was that early CSWD with tacrolimus/MMF and induction antibody therapy would provide equivalent results to CCS with respect to the composite primary end point at 5 years posttransplant. Study results demonstrated no difference between CSWD and CCS groups in the primary end point, nor in its individual components (death, death-censored renal allograft loss, and moderate/severe acute rejection). The magnitude of the difference in BCAR rates between the 2 groups through 5 years was small (7%) and approached, but did not reach statistical significance. In addition, CCS patients experiencing acute rejection were more likely to require antilymphocyte antibody therapy. To put these results in perspective, the acute rejection rates were comparable to those currently observed in Scientific Registry of Transplant Recipients data, and patient and graft survival rates were actually numerically superior to those from recent Scientific Registry of Transplant Recipients data. 5 African Americans, because of high acute rejection rates in previous studies, 13 have been largely excluded from CSWD trials. As noted earlier, the preliminary data on which this trial was based demonstrated low acute rejection rates in African Americans that were only slightly higher than non-African Americans. 4 The present study demonstrated that acute rejection rates in African Americans were not increased with CSWD, and that African American recipient race was not a significant risk factor for acute rejection upon multivariate analysis. This evidence combined with recent reports from single center studies with CSWD in African Americans 18, 19 indicates that the concern of increased acute rejection risk with CSWD in African Americans does not exist under the tacrolimus/MMF/induction therapy immunosuppressive regimen.
No differences were observed between groups in renal allograft survival and function at 5 years. A relatively small increase in death related to infection (P ϭ 0.06) was observed in the CCS group, and a small increase in CAN (P ϭ 0.028) was observed in the CSWD group. However, it is important to note that neither death related to infection nor CAN were predefined end points in the trial. Moreover, neither seemed to affect the end points of patient survival or renal allograft survival. The differences in CAN were observed from posthoc analyses. Protocol-defined renal allograft biopsies were not specified in the study protocol, therefore all CAN diagnoses occurred in renal allograft biopsies performed for evaluation of renal dysfunction (ie, all biopsies were for cause). CSWD patients experienced higher biopsy rates (46% vs. 33% of patients, with a mean of 1.6 vs. 2.0 biopsies/ patient), and when biopsied, CSWD patients were more likely to be diagnosed with CAN than CCS patients (21.6% vs. 12.5%). Therefore, the increased CAN rate was not because of an increased biopsy rate in the CSWD group.
Additional considerations are important for interpreting CAN data. Data regarding pretransplant biopsies were not collected, and therefore the extent to which CAN changes were due to pre-existing donor kidney disease cannot be evaluated. Because renal allograft biopsy results may be subject to variations because of sampling, renal function data were examined by stratifying Cockroft Gault calculated creatinine clearance data. This analysis revealed no differences between CSWD and CCS groups in the proportion of patients with mild (calculated creatinine clearance Ͻ60 mL/min), moderate (calculated creatinine clearance Ͻ40 mL/min), or severe (calculated creatinine clearance Ͻ20 mL/min) degrees of renal dysfunction at 5 years.
A Cox proportional hazards multivariate analysis was performed to assess the influence of risk factors on renal allograft loss. This analysis demonstrated that African American race, deceased donor status, acute rejection, and CAN, but not CSWD, were statistically significant risk factors for graft loss. In summary, (1) CAN was not a predefined end point in the trial, and CAN data were evaluated in a posthoc analysis, (2) the effect of preexisting donor kidney disease on CAN rates cannot be evaluated in this study, (3) Cox proportional hazards analysis showed that African American race, acute rejection, and CAN, but not CSWD are associated with graft loss, (4) no differences were observed between 5-year death censored graft survival between CSWD and CCS groups, (6) no differences were observed between the CCS and CSWD groups in the proportion of patients with mild, moderate, or severe levels of renal dysfunction as measured by calculated creatinine clearance at 5 years. In summary, the small observed increase in CAN was not associated with detectable differences between groups with respect to renal allograft survival and function, and there were no differences in the proportion of patients with significant renal dysfunction. Longer term follow-up may be necessary to determine whether the increased CAN rates may translate into a clinically detectable effect on renal allograft function or survival. As a final note, remarkable graft survival rates were observed in patients without CAN: of 172 patients without CAN in the CSWD group, only 3 (1.7%) lost their renal allograft over the 5-year study period.
A primary benefit of CSWD is improvement in cardiovascular risk. Despite the low maintenance dose in the CCS group (prednisone 5 mg/d) statistically significant differences favoring CSWD were observed in triglycerides, weight gain, and insulin-requiring (but not overall) NODAT at 5-years posttransplant. These differences are of note, as all are involved in development of metabolic syndrome. These observations argue for inclusion of metabolic syndrome as an end point in future early CSWD trials. In perspective, however, patients with end-stage kidney disease have substantial preexisting cardiovascular disease, and smoking and degree of uremia likely exert a much greater influence on cardiovascular risk than the factors examined in this study. In addition, no death risk benefit was evident from CSWD in this study.
An important feature of the study was the incorporation of a low prednisone dose (5mg/d) beginning at 6-months posttransplant. This dose was selected to address the possibility that low maintenance doses of corticosteroids were devoid of adverse effects. Interestingly, the present study provides evidence of significant effects of a 5 mg/d prednisone dose on triglycerides, NODAT, weight gain, and bone complications. Similar to data from the general population where daily prednisone doses of 5 mg/d have been shown to affect bone metabolism, 20 this study indicates that low prednisone doses induce significant, measurable effects on cardiovascular risk.
The quality of this study is highlighted by several observations. First, the proportions of patients who remained in the study who were available for follow-up at 5 years (approximately 80% of patients in both study groups) were remarkably high for a large multicenter trial at 5 years. Similarly, over 63% of patients in both study groups remained on blinded-study drug throughout the entire study. These 2 considerations add significantly to the robustness of the observations from this study. In addition, the low renal allograft loss and death rates experienced by both groups in the study attest to the efficacy of modern immunosuppressive regimens when used in low and moderate risk populations. Potential Sources of Bias and Limitation of Data. One of the limitations of this study is the evaluation of chronic allograft injury or CAN. The possibility of inclusion of protocol renal allograft biopsies was extensively discussed during study design. However, protocol biopsies were not included for a number of reasons. First, previous experiences in other trials have shown that the requirement for protocol renal allograft biopsies has a negative effect on patient consent rates, and is also associated with high rates of patient refusal for biopsies performed at 1 year or later. In addition, concerns were expressed over how to manage clinically silent acute rejection or borderline acute rejection episodes, and whether treatment of these episodes with corticosteroids would negate the benefits of early CSWD. In addition, protocol biopsies would have made the study cost-prohibitive, or would have reduced the overall number of subjects in the study. Power calculations performed during the trial design phase indicated that reduction in the number of subjects would result in the study being inadequately powered with respect to the primary end point.
Another limitation of the present study is the length of the follow-up period. Although the blinded follow-up period of 5 years may be the longest blinding period of any trial to date in the field of transplantation, 5 years is probably not adequate to resolve the issue of the effects of early CSWD on long-term renal allograft survival. Ten-year data may be needed to allow an adequate answer to this question. Generalizability. The present study has shown that tacrolimus/MMF with induction therapy provides low acute rejection rates in primary deceased and living donor transplant recipients without delayed graft function, including African American recipients. A high risk population excluded from the present study was sensitized transplant recipients, a group that has long been considered to be at excessive acute rejection risk with CSWD. However, with induction therapy and modern immunosuppression, excellent patient and graft survival can be achieved in these groups. 14, 21 Additional studies are required to confirm these observations. Overall Evidence. Several open label randomized trials of early CSWD have been reported from Europe 11,22-24 and the United States, 25 most with only short term follow-up (6 -12 months). In addition, a few randomized single center experiences with early corticosteroid withdrawal have been reported. 26, 27 These multicenter and single center randomized CSWD studies have several features in common. First, they have consistently demonstrated low acute rejection rates with early CSWD. Second, they have shown excellent short term renal allograft survival with early CSWD. Finally, these studies have also demonstrated beneficial effects of CSWD on cardiovascular risk factors.
One randomized, controlled, open-label early CSWD multicenter trial from Europe deserves mention as, unlike other trials noted above, long-term follow-up (7 years) has been published. 11 In the most recent report from this trial, actuarial analysis at 9-years posttransplant revealed no increased risk of late allograft loss in steroid-free patients, and moreover, analysis of renal function demonstrated no evidence of deterioration. Therefore, long-term follow-up from 2 multicenter randomized, controlled trials, one open-label (European) and the other double-blinded (current study), provide substantive evidence to counter the Canadian multicenter trial 6 data regarding increased late renal allograft loss with CSWD.
In conclusion, the first double-blinded trial of early CSWD has shown that the risks (acute rejection and longterm renal allograft function) of early CSWD under tacrolimus/MMF/Induction therapy are similar to those with low dose CCS therapy. Early CSWD, however, even compared with long-term low dose prednisone therapy (5 mg/d) provides cardiovascular risk and bone disease benefits. Despite a modest increase in BCAR, early CSWD was not associated with an increased rate of late renal allograft loss or reduced function, and therefore is a reasonable option for unsensitized renal transplant recipients, including African Americans. The remaining caveat is that longer term results are necessary to define renal allograft half lives with early CSWD and chronic maintenance low dose prednisone therapy.
